SCHEMBL3400205

SCHEMBL3400205

O=c1[nH]c2ccc(OCCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 17/20 0.69
SLC6A4 P31645 3/20 0.69
DRD1 P21728 2/20 0.64
HTR2A P28223 1/20 0.54
MCHR1 Q99705 1/20 0.54
DRD4 P21917 1/20 0.52
DRD3 P35462 1/20 0.52
HTR1A P08908 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL254963 0.97 DRD2 (0.70) DRD2SLC6A4DRD1HTR2AMCHR1
SCHEMBL252470 0.85 DRD2 (0.66) DRD2SLC6A4DRD1HTR2AMCHR1
SCHEMBL253416 0.84 DRD2 (0.54) DRD2SLC6A4HTR2AMCHR1HTR1A
SCHEMBL253515 0.83 DRD2 (0.54) DRD2SLC6A4HTR2AMCHR1HTR1A
SCHEMBL10019232 0.83 DRD2 (0.65) DRD2SLC6A4HTR2AMCHR1DRD4
SCHEMBL252359 0.83 DRD2 (0.66) DRD2SLC6A4DRD1DRD4DRD3
SCHEMBL3407608 0.83 DRD2 (0.74) DRD2SLC6A4HTR2AMCHR1DRD4
SCHEMBL253667 0.83 DRD2 (0.66) DRD2SLC6A4DRD1HTR2AMCHR1
SCHEMBL248100 0.82 DRD2 (0.64) DRD2SLC6A4DRD1HTR2AMCHR1
SCHEMBL3410913 0.81 DRD2 (1.00) DRD2SLC6A4DRD1HTR2ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US claimed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-9156822-B2 Functionally selective ligands of dopamine D2 receptors THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2015-10-13 US disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-05-30 US disclosed
WO-2012003418-A2 FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137679-A1 Novel Functionally Selective Ligands of Dopamine D2 Receptors DRD2, AVPR2, NTSR2 DRD2 1/4885SLC6A4 210/4885DRD1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.